4 documents

Read All
20:02 , Aug 31, 2017 |  BC Innovations  |  Targets & Mechanisms

Necroptosis strikes again

Adding to the list of necroptosis-related pathologies, a group from Arizona State University has shown the cell death pathway is activated in Alzheimer’s disease. The data, published last month in Nature Neuroscience , identify potential...
Read More
07:00 , Sep 12, 2016 |  BioCentury  |  Strategy

Dealing Denali

Denali Therapeutics Inc .'s recent unveiling of 11 deals provides the first glimpse of how the company plans to deploy its nearly $350 million war chest to target neurodegenerative diseases. The company has previously said...
Read More
07:00 , Sep 5, 2016 |  BC Week In Review  |  Company News

Incro Pharmaceuticals, Denali Therapeutics deal

Denali acquired Incro, which was developing an undisclosed small molecule inhibitor of receptor-interacting serine-threonine kinase 1 ( RIPK1 ; RIP1 ) with CNS penetrant properties. Denali hopes the study’s data will inform future trials in...
Read More
07:00 , Aug 25, 2016 |  BC Extra  |  Top Story

Denali unveils $130M funding, series of deals

Denali Therapeutics Inc. (South San Francisco, Calif.) disclosed Thursday that it raised $130 million in a series B round and made five deals to flesh out its pipeline. The company is pursuing neurodegenerative diseases including...
Read More